Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.69 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130854 | 1.00 | DRD2 (0.69) | DRD2NR1H2NR1H3SIGMAR1DRD3 | |
| SCHEMBL7130859 | 1.00 | DRD2 (0.69) | DRD2NR1H2NR1H3SIGMAR1DRD3 | |
| SCHEMBL7518870 | 0.92 | DRD2 (0.60) | DRD2NR1H2NR1H3SIGMAR1DRD3 | |
| SCHEMBL7518873 | 0.89 | DRD2 (0.57) | DRD2NR1H2NR1H3SIGMAR1DRD3 | |
| SCHEMBL7137393 | 0.84 | DRD2 (0.68) | DRD2SIGMAR1DRD3 | |
| SCHEMBL7137390 | 0.84 | DRD2 (0.68) | DRD2SIGMAR1DRD3 | |
| SCHEMBL7137397 | 0.84 | DRD2 (0.68) | DRD2SIGMAR1DRD3 | |
| SCHEMBL13406112 | 0.83 | ACHE (0.58) | DRD2SIGMAR1ACHECCR5 | |
| SCHEMBL13406114 | 0.83 | ACHE (0.58) | DRD2SIGMAR1ACHECCR5 | |
| SCHEMBL4825273 | 0.82 | DRD2 (1.00) | DRD2NR1H2NR1H3SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240141-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109532-A1 | Modulators of dopamine neurotransmission | OPRD1, CHRNA5, OPRM1 | DRD2 12/4885NR1H2 244/4885NR1H3 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.